Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sujay Srinivas

Showing results (21-30 of 47) with videos related to

Pageof 5
Sort By:
Journal of Gastrointestinal Cancer|June 27, 2023
Gemcitabine, Cisplatin, and Nab-Paclitaxel as a First-Line Therapy for Advanced Biliary Tract CancersSandeep Gedela, Pritesh Munot, Arvind Vaidyanathan, et al.
Cancer|June 21, 2025
Efficacy of losartan plus modified FOLFIRINOX versus modified FOLFIRINOX in advanced pancreatic cancers: A randomized clinical trial (AFPAC Study)Anant Ramaswamy, Prabhat Bhargava, Vikram Gota, et al.
Ecancermedicalscience|June 10, 2022
Outcomes of Ewing sarcoma in adults over 40 years of age from a low-middle income countryGoutam Panda, Arun Chandrasekharan, Shasanka Das, et al.
The Oncologist|March 11, 2022
Phase I Study Evaluating Dose De-escalation of Sorafenib with Metformin and Atorvastatin in Hepatocellular Carcinoma (SMASH)Vikas Ostwal, Anant Ramaswamy, Vikram Gota, et al.
Pediatric Blood & Cancer|May 15, 2021
Adolescent-adult nonmetastatic Ewing sarcoma-Experience from a large developing countryJyoti Bajpai, Goutam Santosh Panda, Arun Chandrasekharan, et al.
Cancer Medicine|February 16, 2021
A real-world data of Immune checkpoint inhibitors in solid tumors from IndiaVanita Noronha, George Abraham, Vijay Patil, et al.
The Lancet. Oncology|January 15, 2024
Low-dose versus standard-dose olanzapine with triple antiemetic therapy for prevention of highly emetogenic chemotherapy-induced nausea and vomiting in patients with solid tumours: a single-centre, open-label, non-inferiority, randomised, controlled, phase 3 trialJyoti Bajpai, Venkatesh Kapu, Sushmita Rath, et al.
Journal of Immunotherapy and Precision Oncology|June 6, 2022
Meeting Proceedings of the 2nd Annual Immuno-Oncology Society of India Conference (I-OSICON-2020), Mumbai, IndiaJyoti Bajpai, Sujay Srinivas, George Abraham, et al.
JCO Global Oncology|November 30, 2023
Survival of Trial-Like and Non-Trial-Like Patients With Immunotherapy in Advanced Hepatocellular Carcinoma in Real World: A Collaborative Multicenter Indian Study (IMHEP)Anant Ramaswamy, Anand Kulkarni, George John, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 5, 2024
Bevacizumab Erlotinib Switch Maintenance in Chemo-Responsive Advanced Gallbladder and Cholangiocarcinoma (BEER BTC): A Multicenter, Open-Label, Randomized, Phase II TrialAnant Ramaswamy, Prabhat Bhargava, Sujay Srinivas, et al.
Pageof 5

Showing results (21-30 of 47) with videos related to

Sort By:
Pageof 5
Journal of Gastrointestinal Cancer|June 27, 2023
Gemcitabine, Cisplatin, and Nab-Paclitaxel as a First-Line Therapy for Advanced Biliary Tract CancersSandeep Gedela, Pritesh Munot, Arvind Vaidyanathan, et al.
Cancer|June 21, 2025
Efficacy of losartan plus modified FOLFIRINOX versus modified FOLFIRINOX in advanced pancreatic cancers: A randomized clinical trial (AFPAC Study)Anant Ramaswamy, Prabhat Bhargava, Vikram Gota, et al.
Ecancermedicalscience|June 10, 2022
Outcomes of Ewing sarcoma in adults over 40 years of age from a low-middle income countryGoutam Panda, Arun Chandrasekharan, Shasanka Das, et al.
The Oncologist|March 11, 2022
Phase I Study Evaluating Dose De-escalation of Sorafenib with Metformin and Atorvastatin in Hepatocellular Carcinoma (SMASH)Vikas Ostwal, Anant Ramaswamy, Vikram Gota, et al.
Pediatric Blood & Cancer|May 15, 2021
Adolescent-adult nonmetastatic Ewing sarcoma-Experience from a large developing countryJyoti Bajpai, Goutam Santosh Panda, Arun Chandrasekharan, et al.
Cancer Medicine|February 16, 2021
A real-world data of Immune checkpoint inhibitors in solid tumors from IndiaVanita Noronha, George Abraham, Vijay Patil, et al.
The Lancet. Oncology|January 15, 2024
Low-dose versus standard-dose olanzapine with triple antiemetic therapy for prevention of highly emetogenic chemotherapy-induced nausea and vomiting in patients with solid tumours: a single-centre, open-label, non-inferiority, randomised, controlled, phase 3 trialJyoti Bajpai, Venkatesh Kapu, Sushmita Rath, et al.
Journal of Immunotherapy and Precision Oncology|June 6, 2022
Meeting Proceedings of the 2nd Annual Immuno-Oncology Society of India Conference (I-OSICON-2020), Mumbai, IndiaJyoti Bajpai, Sujay Srinivas, George Abraham, et al.
JCO Global Oncology|November 30, 2023
Survival of Trial-Like and Non-Trial-Like Patients With Immunotherapy in Advanced Hepatocellular Carcinoma in Real World: A Collaborative Multicenter Indian Study (IMHEP)Anant Ramaswamy, Anand Kulkarni, George John, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 5, 2024
Bevacizumab Erlotinib Switch Maintenance in Chemo-Responsive Advanced Gallbladder and Cholangiocarcinoma (BEER BTC): A Multicenter, Open-Label, Randomized, Phase II TrialAnant Ramaswamy, Prabhat Bhargava, Sujay Srinivas, et al.
Pageof 5